Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00428610 · ClinicalTrials.gov registry record · Phase 2
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT00428610 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 103 participants.
The verdict
NCT00428610, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The primary objective is to determine whether LY573636-sodium (hereafter referred to as LY573636) is effective in treating platinum-resistant ovarian cancer. Patients will receive an intravenous infusion of study drug once every 28 days. Computed tomography (CT) scans and CA-125 tests will be done before the first dose and then after every other treatment.
Interventions
- DRUG LY573636-sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2007-02 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00428610
The ClinicalTrials.gov registry entry for NCT00428610 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY573636-sodium is the first listed.
NCT00428610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00428610 about?
NCT00428610 is a clinical study titled "A Study of Chemotherapy Treatment for Patients With Ovarian Cancer". The primary objective is to determine whether LY573636-sodium (hereafter referred to as LY573636) is effective in treating platinum-resistant ovarian cancer. Patients will receive an intravenous infusion of study drug once every 28 days. Computed tomography (CT) scans and CA-125 tests will be done b...
What is the current status of trial NCT00428610?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2007-02. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00428610?
The interventions under investigation include: LY573636-sodium (DRUG).
Who is sponsoring clinical trial NCT00428610?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.